The table below shows NewAmsterdam Pharma Company N.V.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$3.04M
$348.00K
$19.14M
$2.98M
$29.11M
$2.28M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$38.01M
$30.97M
$27.52M
$44.75M
$35.70M
$38.38M
SG&A
NAMS annual revenue (10-K history)
NewAmsterdam Pharma Company N.V. reported annual revenue of $22.50M for fiscal year 2025. That is down 50.6% from $45.56M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.